abstract |
The invention belongs to the field of biomedicine, and particularly relates to the use of biomarkers in predicting the sensitivity of bevacizumab. Specifically, the biomarkers include KCNT2, FLJ33534, and CACHD1; preferably, the predicting bevacizumab sensitivity is predicting the sensitivity of rectal cancer patients to bevacizumab. |